Sarepta Therapeutics traded at $125.71 this Friday December 2nd, increasing $2.73 or 2.22 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics gained 19.71 percent. Over the last 12 months, its price rose by 60.14 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 110.82 by the end of this quarter and at 100.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
125.71
Daily Change
2.22%
Yearly
60.14%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 4,405.00 -192.00 -4.18% 54.75%
Acadia Pharmaceuticals 15.56 0.22 1.43% -17.19%
Agios Pharmaceuticals 30.20 0.81 2.76% -11.75%
Alnylam Pharmaceuticals 226.84 6.59 2.99% 32.38%
Amgen 284.20 -1.74 -0.61% 40.39%
Avrobio Inc 0.83 -0.06 -7.25% -76.88%
BioCryst Pharmaceuticals 12.79 -0.17 -1.28% 11.84%
Biogen 300.83 -1.02 -0.34% 34.35%
Bluebird Bio 8.24 0.63 8.21% -17.24%
BioMarin Pharmaceutical 105.96 2.94 2.85% 27.74%
Capricor Therapeutics 4.48 0.15 3.46% 55.02%
Esperion Therapeutics 7.22 0.28 4.05% 37.54%
Gilead Sciences 88.31 0.41 0.47% 26.96%
Intercept Pharmaceuticals 14.70 0.13 0.89% -5.95%
Incyte Corp 82.18 1.50 1.86% 24.93%
Insmed 19.31 0.19 0.99% -25.42%
Ionis Pharmaceuticals 40.00 -0.20 -0.50% 51.57%
Eli Lilly 372.61 2.28 0.62% 51.73%
Moderna Inc 179.57 -1.91 -1.05% -41.45%
Mirati Therapeutics 92.94 1.44 1.57% -29.78%
Neurocrine Biosciences 126.78 0.47 0.37% 59.11%
Nektar Therapeutics 3.05 0.17 5.93% -71.83%
Lumos Pharma Inc. 5.10 0.005 0.09% -28.67%
Novavax 15.92 -0.93 -5.52% -90.08%
Pfizer 51.02 -0.06 -0.12% -5.99%
PTC Therapeutics 41.69 0.14 0.32% 17.89%
Ultragenyx Pharmaceutical 38.06 0.25 0.66% -49.93%
Regeneron Pharmaceuticals 763.22 1.98 0.26% 20.16%
Roche Holding 309.15 -0.85 -0.27% -14.66%
Sanofi 85.84 -1.61 -1.84% 2.47%
Sangamo BioSciences 3.60 0.04 0.98% -55.62%
Sarepta Therapeutics 125.71 2.73 2.22% 60.14%
Vertex Pharmaceuticals 318.60 -2.16 -0.67% 56.32%

Indexes Price Day Year
USND 11389 -93.25 -0.81% -24.50%
US2000 1883 1.39 0.07% -12.79%

Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.